Revolutionizing Cancer Drug Development
Luis Voloch discusses the innovative approach of Immunai, a drug development company that focuses on cancer immunotherapies. By targeting immune cells instead of cancer cells directly, they aim to enhance the body's ability to fight cancer. With a strong emphasis on data and machine learning, Immunai combines the expertise of computer scientists, mathematicians, and biotech scientists to revolutionize the field of cancer drug development.In this clip
From this podcast
The Gradient
Luis Voloch: AI and Biology
Related Questions